VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SITC 2021 | Tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the results of a Phase Ib study evaluating tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma (NCT02535078). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter